Appletree Medical Group

appletreemedicalgroup.com

For almost 30 years, Appletree Medical Group has focused on improving community healthcare. Thanks to years of continuous innovation, we have grown to become one of the largest multidisciplinary community health groups in Canada, preferred by both patients and health professionals alike. Whether by visiting one of our 75 medical centres or telemedicine sites, or connecting through our Virtual Care app, Appletree patients are given greater control over their healthcare.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

news image

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More

RESEARCH

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

news image

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

news image

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More

EUROFINS DISCOVERY ANNOUNCES COLLABORATION WITH A SWISS-BASED BIOTECH COMPANY AMPHILIX AG

Eurofins Discovery | November 04, 2020

news image

Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage ...

Read More
news image

MEDICAL

WUXI ATU AND WUGEN ANNOUNCE MANUFACTURING PARTNERSHIP TO EXPEDITE THE DELIVERY OF NOVEL CELL CANCER IMMUNOTHERAPIES

Wugen | June 16, 2022

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy produ...

Read More
news image

RESEARCH

PHARMABCINE TO PRESENT UPDATED INTERIM DATA FROM THE ONGOING PHASE IB TRIAL OF OLINVACIMAB AND PEMBROLIZUMAB COMBINATION THERAPY

PharmAbcine | December 08, 2020

PharmAbcine Inc., a clinical-stage biotech organization focusing in on the improvement of completely human antibody therapeutics, declared today that the organization will introduce the refreshed break information from the continuous stage Ib trial of olinvacimab and pembrolizumab combination therapy in metastatic triple-negative breast cancer (mTNBC) patients at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020) occurring for all intents and purposes over December 8-11, 2020.
Read More

news image

AKREVIA REBRANDS AS XILIO THERAPEUTICS, SNAGS $100 MILLION IN SERIES B

BioSpace | March 02, 2020

Two years after Cambridge, Mass.-based Akrevia Therapeutics launched, the company has rebranded itself as Xilio Therapeutics and secured $100.5 million in a Series B financing round that will be used to advance its lead therapeutic candidates into clinical studies. The financing will be used to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb) through Investigational New Drug (IND) enabling studies and into Phase I clin...

Read More
news image

EUROFINS DISCOVERY ANNOUNCES COLLABORATION WITH A SWISS-BASED BIOTECH COMPANY AMPHILIX AG

Eurofins Discovery | November 04, 2020

Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage ...

Read More